Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-19-006657

Options or other derivatives

  • Chief Business Officer acquired 45,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Klein Lawrence Otto Chief Business Officer 2019-03-05 Grant or award · Stock Option (Right to Buy) +45,000 45,000 D: show line 1 in the form
Loading xslF345X03/doc4.xml…